NANO Nuclear Energy Inc.

NASDAQ•NNE

執行長: Mr. Jiang Yu

板塊: Industrials

行業: Industrial - Machinery

上市日期: 2000-01-05

NANO Nuclear Energy Inc. operates as a microreactor technology company. The company is developing ZEUS, a solid-core battery reactor, and ODIN, a low-pressure coolant reactor. It is also developing a high-assay low-enriched uranium fabrication facility to supply fuel to the nuclear reactor industry and fuel transportation and nuclear consultation businesses. The company was founded in 2021 and is based in New York, New York.

聯絡資訊

10 Times Square, 30th Floor, New York, NY, 10018, United States

212-634-9206

nanonuclearenergy.com

市值

$1.10B

本益比 (TTM)

-30.2

20.4

股息率

52周最高

$60.87

52周最低

$17.26

52周範圍

21%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基於 4 年期基本面

疲弱 • 2.2 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2022-2025

財務儀表板

Q1 2026 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.13+0.00%

近4季度走勢

自由現金流

-$3.99B+0.00%

近4季度走勢

2026 Q1 財報亮點

核心亮點

Strong Financing Inflow Net cash from financing $381.33M USD; October 2025 private placement raised $400.00M gross USD.

R&D Spending Accelerates R&D expense $5.40M USD for three months, up 497% versus prior period's $0.90M USD spend.

Cash Position Strengthened Cash equivalents reached $577.53M USD December 31, 2025; working capital $576.43M USD.

Reactor Licensing Progress NRC approved Fuel Qualification Methodology Topical Report; targeting construction permit submission first half 2026.

關注風險

Future Funding Uncertainty Future capital needs require equity/debt financing; inability to raise funds could materially affect operations failure.

Regulatory Timeline Risks KRONOS reactor licensing timeline uncertain; NRC review timing outside management control, potentially delaying commercialization.

Operating Loss Widening Net loss $6.52M USD for quarter, nearly doubling prior period's $3.11M USD loss; cash used in operations $3.99M USD.

SEC Investigation Ongoing Received subpoena regarding two service providers; cannot predict outcome of SEC investigation initiated April 2025.

未來展望

KRONOS Commercialization Target Aiming for NRC construction permit submission first half 2026; initial operation projected between 2030 and 2031.

Illinois Facility Investment Plan investment over $12M USD in Illinois facility for manufacturing and R&D; expecting $6.8M USD in incentives.

Consulting Revenue Near Term Generating small consulting revenue in 2025; formal launch dependent on acquiring existing revenue-generating businesses.

ODINT Reactor Sale Considered Signed Letter of Intent for proposed sale of ODINT microreactor design to monetize investment and focus resources.

同行對比

營業收入 (TTM)

ZIM

$7.59B

+1.6%

$2.52B

-19.2%

ENOV

$2.25B

+6.7%

毛利率 (最新季度)

ENOV

60.7%

+3.2pp

EPAC

49.6%

-1.8pp

SXI

39.7%

+2.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
ZIM	$3.48B	3.5	25.2%	52.1%
SXI	$3.21B	59.2	7.7%	40.1%
ATS	$3.16B	228.2	1.1%	35.6%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月13日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料